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Introduction
Alzheimer's disease (AD) represents the most common form of dementia, characterized by the accumulation of amyloid b (Ab) in extracellular plaques and hyperphosphorylated tau in intracellular neurofibrillary tangles (NFTs). 1 The majority of AD patients additionally develop amyloid lesions in the cerebrovasculature. 2 Cerebral amyloid angiopathy (CAA) describes an AD-associated vessel disorder, defined by the deposition of Ab in leptomeningeal and/or parenchymal arteries, veins, and capillaries. 3 Cerebrovascular Ab structurally resembles Ab fibrils in plaques of AD patients. 4 The overall abundance of CAA and plaques in AD 2, 5 and the spatio-temporal relation between CAA and plaques in the pathogenesis of AD [6] [7] [8] suggest a pathogenic link between both pathologies.
Recently, we revealed a hierarchical sequence for the deposition of different Ab species in the pathogenesis of AD-related amyloid plaques. 9 Three biochemical stages of Ab aggregate maturation in plaques (B-Ab plaque stages) were identified based on the immunohistochemical detection of Ab and its modified species. B-Ab plaque stage 1 was defined by the parenchymal deposition of Ab lacking N-terminal truncated, pyroglutaminated Ab (Ab N3pE ) and phosphorylated Ab (Ab pS8 ), whereas Ab including Ab N3pE was prevalent in B-Ab plaque stage 2. B-Ab plaque stage 3, finally, exhibited Ab pS8 within the parenchymal Ab aggregates in addition to other forms of Ab including Ab N3pE. 9 Post-translational modification of Ab by N-terminal truncation and pyroglutamination as well as phosphorylation affect the aggregation, stability, and toxicity of Ab. 10, 11 In particular pyroglutamination at glutamate 3 and phosphorylation at serine 8 promote aggregation, thereby enhancing metabolic stability and toxicity of Ab. [12] [13] [14] [15] [16] Despite the abundance of Ab N3pE and Ab pS8 in plaques and CAA of AD patients, 9, 15, [17] [18] [19] [20] the molecular composition of CAA lesions and its relation to the progression of AD remain enigmatic. To compare amyloid deposition in CAA and plaques, we analyzed the medial temporal and occipital lobe of control, pathologically-defined preclinical AD (p-preAD), and symptomatic AD cases for the presence of Ab and its modified forms Ab N3pE and Ab pS8 in CAA-affected blood vessels.
Materials and Methods

Neuropathology
Brain tissue originated from the brain bank of the "Laboratory of Neuropathology" at the "University of Ulm" (Germany) that collected brain tissue in accordance with German legal regulations. Collection of brain tissue and experimental analyses of this project were approved by the ethics committees of the Universities of Ulm (Germany), Bonn (Germany), and KU Leuven (Belgium) where experiments have been performed (Votes Nos. Bonn: 161/01, 238/04; Ulm: 238/07, 54/08, 57/12; Leuven: S-58102, S-59295).
The brain collection consists of hospital-based autopsy cases that were included into the brain bank at the time point of autopsy. The clinical information, therefore, included only information from files that could be reviewed retrospectively in the respective hospital. Longitudinal data and data from neuropsychological tests were not available.
Morphological analysis of cerebrovascular and parenchymal Ab lesions was performed in autopsy brains of 24 control, 27 p-preAD, and 20 sporadic AD cases ( Table 1 ). The diagnosis of AD was performed neuropathologically with consideration of clinical information about the cognitive status. Control cases were defined by absence of amyloid plaques including cases with primary age-related tauopathy 21 and occasionally CAA. Non-demented cases with AD pathology, comprising Ab plaques and NFTs, were designated as p-preAD cases, whereas symptomatic AD cases were characterized by substantial AD pathology and impairment of cognition. 1, 22 Following autopsy, brains were fixed in a 4% aqueous solution of formalin and tissue from both the medial temporal and occipital lobe was embedded in paraffin and cut into sections of 12 lm. Neuropathological diagnosis of AD was performed according to established guidelines of the "National Institute of Aging-Alzheimer's Association" (NIA-AA AD degree) 1 and included (1) the assessment of NFT distribution (Braak-NFT stage) 23, 24 on the basis of Gallyas' silver impregnation 24 and/or immunohistochemical staining of abnormal phosphorylated tau (AT8, 1:1000, Pierce Endogen; Rockford, USA), 25 (2) the assignment of neuritic plaque density (Consortium to Establish a Registry for AD (CERAD) score) 26 on the basis of Gallyas' silver impregnation 24 and/or immunohistochemical staining of abnormal phosphorylated tau (AT8, 1:1000, Pierce Endogen; Rockford, USA), 1 and (3) the evaluation of amyloid plaque distribution in the medial temporal lobe (Ab-MTL phase) 27 on the basis of immunohistochemical staining for Ab [17] [18] [19] [20] [21] [22] [23] [24] (4G8, 1:5000, Covance; Princeton, USA). Apolipoprotein E (APOE) genotypes were determined by restriction isotyping of unfixed brain tissue with HhaI 28 (Table 1 ). The severity of CAA-related vessel wall destruction (CAA severity) was graded according to Vonsattel et al. 29 ; and the stage of the anatomical expansion of CAA throughout the brain (CAA stage) was rated according to Thal et al. 30 CAA with affection of capillaries was referred to as CAA type 1, and CAA without capillary Ab deposits was designated as CAA type 2. 31 Medical examination of control, p-preAD, and AD cases was performed one to four weeks prior to death according to standardized protocols and included the Ab-MTL phase 6 Braak-NFT assessment of (1) cognition (including short term and long term memory), (2) speech, writing, and reading, (3) selfdependence and self-care, (4) habit of eating, (5) bladder and bowel continence, and (6) orientation within the hospital setting. 8 Clinical data were used to retrospectively assess clinical dementia rating scores (CDR scores) 32 and for information about arterial hypertension, diabetes mellitus, and alcohol abuse. Cases with CDR scores ≥ 0.5 in conjunction with intermediate to high NIA-AA AD degrees were considered as symptomatic AD cases. 1 Due to missing clinical data, CDR scores could not be obtained for 5 of 24 control, 2 of 27 p-preAD, and 2 of 20 AD cases (Table 1) .
Immunohistochemistry
Following deparaffinization, hydration, and blocking, sections of the medial temporal and occipital lobe were incubated for 24 h at room temperature with anti-Ab [17] [18] [19] [20] [21] [22] [23] [24] (4G8, 1:5000, Covance; Princeton, USA; formic acid pretreatment), anti-Ab N3pE 20 (1:100, IBL; Hamburg, Germany; formic acid/microwave pretreatment), or antiAb pS8 12,33 (SA5434/1E4E11, 1:5; formic acid/microwave pretreatment) antibodies. The antibodies used in this study to detect phosphorylated or pyroglutaminated Ab were raised specifically against synthetic Ab peptides carrying the phosphorylation or pyroglutamate modification and recognize phosphorylated serine or pyroglutamate residues selectively in the context of the Ab amino acid sequence. Primary antibodies were detected with biotinylated secondary antibodies and visualized with the ABC method (Vector Laboratories; Burlingame, USA) and 3,3 0 -diaminobenzidine (DAB; brown color) as chromogen. Sections were counterstained with hematoxylin. Positive and negative controls were performed.
Sensitivity and specificity of phosphorylation-state specific polyclonal (SA5434) and monoclonal (1E4E11) antibodies were examined by preabsorption with synthetic Ab peptides followed by western immunoblotting and/or immunohistochemistry using brain tissue from transgenic mouse models and human AD cases. 12, 17, 33 Additional staining with antibodies against Ab 1-17 (6E10; 1:1,250, Covance; Princeton, USA; formic acid pretreatment) was performed on selected sections as described previously. 9 Analysis of Ab, Ab N3pE , and Ab pS8 deposition in CAA Analysis of CAA was conducted in the medial temporal lobe of control, p-preAD, and AD cases stained for Ab, Ab N3pE , or Ab pS8 ( Table 1 ). Cases that exhibited Ab deposits in leptomeningeal and/or parenchymal vessels were considered positive for CAA independent of the severity and extent of CAA pathology. Vascular Ab deposition was Ab-MTL phase 6 Braak-NFT clinical dementia rating (CDR) score. 64 6 Ab -medial temporal lobe (MTL) phase. 27 7 Braak -neurofibrillary tangle (NFT) stage. 23,25 8 Consortium to Establish a Registry for Alzheimer's disease (CERAD) score. 
Statistical analysis
Statistical analysis was performed using SPSS Statistics 22 (IBM; Chicago, USA). Partial Spearman's rank correlation (control for age/gender) was used to evaluate the association amongst CAA-and AD-related parameters. Multinomial logistic regression (control for age/gender) was applied to compare Ab pathology groups for their association with CAA-and AD-related parameters, vascular risk factors, and alcohol abuse. Linear regression (control for age/gender) was used to determine the effect of B-CAA and B-Ab plaque stages on NIA-AA AD degree, CDR score, vascular risk factors, and alcohol abuse. B-Ab plaque stages and amyloid plaque loads used for statistical analysis were obtained from a previous publication in which the present cases were analyzed for the biochemical composition of Ab aggregates in plaques. 9 
Results
Molecular differentiation of amyloid deposition in CAA
To analyze amyloid composition of CAA, brains of control (including cases with CAA in the absence of plaques), p-preAD, and AD cases were stained with antibodies , NIA-AA AD degree 1, 65 . Values in bold represent statistically significant results. Absolute (number of cases in bold) and relative (percentage of cases in italics) frequency of B-Ab plaque and B-CAA stages. Assignment of cases with CAA and/or plaque pathology to the Ab pathology groups is color-coded [light gray boxes = group 1 (CAA-predominant Ab maturation); black boxes = group 2 (equal maturation of Ab in CAA and plaques); dark gray box = group 3 (plaque-predominant Ab maturation)] whereas control cases without CAA and AD pathology were indicated in white.
against non-modified epitopes of Ab (Ab 17-24 , Ab 1-17 ) or the post-translationally modified species Ab N3pE and Ab pS8 . Deposition of Ab, including Ab N3pE and Ab pS8, was detected in arteries, veins, and/or capillaries of the leptomeninges and/or the parenchyma (Fig. 1) . Of the 35 cases with CAA detected through anti-Ab 17-24 staining, 32 cases (91.4%) also showed vascular Ab N3pE , whereas vascular Ab pS8 was limited to 21 cases with CAA (60%). Thereby, Ab pS8 was exclusively detected in cases also exhibiting Ab N3pE . Triple label immunofluorescence revealed that nonmodified (6E10-positive) Ab, Ab N3pE , and Ab pS8 could colocalize in the same vessels (Fig. S1) . Moreover, all cases in which CAA could be detected with antibodies against Ab 17-24 also showed a positive staining for Ab [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Our findings indicate the sequential deposition of distinct post-translationally modified Ab species in CAA analogous to the biochemical stages of Ab deposition in amyloid plaques (B-Ab plaque stages), 9 defining three biochemical (immunohistochemical) stages of CAA (B-CAA stages). B-CAA stage 1 was characterized by deposition of Ab in the absence of Ab N3pE and Ab pS8 ; B-CAA stage 2 was defined by the additional deposition of Ab N3pE ; and B-CAA stage 3 corresponded to the deposition of Ab including Ab N3pE and Ab pS8 (Fig. 1) . In the combined cohort of control, p-preAD, and AD cases, three of 35 cases with CAA (8.6%) presented with B-CAA stage 1, whereas B-CAA stage 2 was prevalent in 11 of 35 cases with CAA (31.4%). Twenty one of 35 cases with CAA (60%) exhibited B-CAA stage 3 ( Table 1) .
The B-CAA stages highly correlated with the overall anatomical expansion of CAA as represented by the CAA stage 30 and the severity of CAA-related vessel wall damage according to the Vonsattel grading 29 (P < 0.001, Table 2 ).
Heterogeneous amyloid deposition in CAA and plaques
Analysis of Ab deposition in CAA and plaques revealed heterogeneity between B-Ab plaque and B-CAA stages. On the one hand, B-CAA stage 1 and 2 could be detected in cases with B-Ab plaque stage 3. Two cases with B-Ab plaque stage 3 even presented without CAA. On the other hand, cases with B-CAA stage 3 could exhibit initial stages of amyloid deposition in plaques (B-Ab plaque stage 2) or no amyloid plaques at all ( Table 1 ). The distribution of the distinct B-Ab plaque stages within the different B-CAA stages of control, p-preAD, and AD cases indeed supported the heterogeneous deposition of modified Ab in CAA and plaques (Table 3) . Accordingly, analysis of control, p-preAD, and AD cases with Ab pathology revealed no significant correlation between the B-CAA stages and the Ab/Ab N3pE plaque load (P ≥ 0.137, Table 2 ). However, the B-CAA stages weakly correlated with the Ab pS8 plaque load (P = 0.001, Table 2 ). The and CAA severity 29 (A), to Ab-MTL phases, 27 Braak-NFT stages, 23 and CERAD scores 26 (B), and to Ab, Ab N3pE , and Ab pS8 plaque loads (C).
dissociation of the B-CAA stages from the plaque load became particularly obvious when restricting the correlation analysis to cases with CAA pathology (≥ B-CAA stage 1) (P ≥ 0.761, Table 2 ). Based on the distribution of the B-Ab plaque and B-CAA stages, cases with Ab pathology could be subclassified into three groups of Ab aggregate maturation: group 1 corresponded to cases with biochemically more advanced maturation of CAA pathology (CAA-predominant group: B-CAA stage > B-Ab plaque stage; this group included CAA cases without plaque pathology); group 2 comprised cases with equal biochemical maturation of Ab aggregates in CAA and plaques (equal maturation group: B-CAA stage = B-Ab plaque stage; this group contained only cases with end-stage Ab pathology); and group 3 referred to cases with biochemically more advanced maturation of plaque pathology (plaque-predominant group: B-CAA stage < BAb plaque stage; this group included 16 cases without CAA). Seven of 51 cases with Ab pathology (13.7%) were assigned to group 1 whereas group 3 comprised 27 of 51 cases with Ab pathology (53.0%). Notably, 17 of 51 cases (33.3%) exhibited equal maturation of Ab in CAA and plaques, thus being classified into group 2 ( Table 3) .
Association of Ab pathology groups with CAA-and AD-related pathology
Comparison of the CAA-predominant (group 1), plaquepredominant (group 3), and equally maturating (group 2) cases by multinomial logistic regression (controlled for age and gender) revealed no association with the CAA stage and severity when comparing groups 1 and 2 (P ≥ 0.535, Table 4 ). However, group 3 exhibited lower levels of CAA severity and expansion throughout the brain than the other two groups (P ≤ 0.016, Table 4 ; Fig. 2A) .
Notably, cases with capillary CAA (CAA type 1) more likely belonged to group 2 than to group 3 compared to cases without capillary Ab deposits (CAA type 2) or without CAA (P = 0.035, Table 4 ). No significant difference became obvious between groups 1 and 2, or groups 1 and 3 (P ≥ 0.452, Table 4 ). In contrast, the presence of CAA type 2 significantly increased the probability of a case for belonging to group 1 compared to group 3 (P = 0.040, Table 4 ) that could not be observed for group 2 (P ≥ 0.162, Table 4 ). The APOE e4 allele frequency was higher in group 2 compared to group 3 (P = 0.021, Table 4 ). Furthermore, group 1 (P ≤ 0.042, Table 4 ), but not groups 2 and 3 (P = 0.160, Table 4 ), was associated with arterial hypertension. The differential prevalence of arterial hypertension within the Ab pathology groups indeed supported the association with CAA-related Ab maturation (Table 5) . None of the groups showed an association with diabetes mellitus or alcohol abuse (P ≥ 0.207, Table 4 ).
Cases in groups 2 or 3 presented with higher Ab-MTL phases compared to group 1 (P ≤ 0.042, Table 4 ). However, no significant difference was detected between groups 2 and 3 (P = 0.134, Table 4 ). Higher Braak-NFT stages were observed in group 2 (equal maturation) compared to group 1 with CAA-predominant Ab pathology (P = 0.037, Table 4 ) whereas no significant difference became obvious between groups 1 and 3, or groups 2 and 3 (P ≥ 0.131, Table 4 ). Likewise, CERAD scores for neuritic plaque pathology were higher in group 2 than in groups 1 and 3 (plaque-predominant maturation) (P ≤ 0.034, Table 4 ). Groups 1 and 3 did not differ significantly (P = 0.433, Table 4 ; Fig. 2B) .
Notably, cases of groups 1 and 2 showed significant differences in the Ab, Ab N3pE , and Ab pS8 plaque load (P ≤ 0.048, Table 4 ). Comparison of group 3 with groups Absolute (number of cases in bold) and relative (percentage of cases in italics) frequency of (no) arterial hypertension within Ab pathology groups. Of the 20 control cases without Ab pathology that could not be assigned to either of the Ab pathology groups, seven cases (35%) exhibited arterial hypertension, whilst arterial hypertension was not observed in 13 cases (65%). 
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1 or 2, however, revealed no association with the Ab, Ab N3pE , or Ab pS8 plaque load (P ≥ 0.057, Fig. 2C ).
Since six cases presented with vascular dementia (VD), corticobasal degeneration (CBD), Lewy body disease (LBD), and/or argyrophilic grain disease (AGD) additional to AD pathology that might contribute to cognitive decline, multinomial logistic regression of CDR scores was restricted to cases with "pure" CAA and/or AD pathology, thereby preventing the distortion of statistics through the contribution of these co-morbidities to dementia. Notably, group 2 exhibited higher CDR scores compared to group 1 (P < 0.001, Table 4 ). No significant difference was detected between groups 1 and 3, or groups 2 and 3 (P ≥ 0.389, Table 4 ).
Association of B-CAA stages with AD-related pathology, risk factors, and clinical progression CAA was prevalent in 4 of 24 control cases (16.7%), 11 of 27 p-preAD cases (40.7%), and 20 of 20 AD cases (100%). All B-CAA stages could be detected in p-preAD and AD cases, whereby two of 11 p-preAD cases with CAA (18.2%) and one of 20 AD cases with CAA (5%) exhibited B-CAA stage 1. B-CAA stage 2 was prevalent in one of 11 p-preAD (9.1%) and seven of 20 AD (35%) cases with CAA. B-CAA stage 3, however, became obvious in eight of 11 p-preAD cases with CAA (72.7%) but only in 12 of 20 AD cases with CAA (60%). In this context, it is important to re-note that 16 of 27 p-preAD cases (59.3%) did not exhibit CAA. Three of four control cases with CAA (75%) exhibited B-CAA stage 2, whereas B-CAA stage 3 was prevalent in one of four control cases with CAA (25%) ( Table 1) . Partial Spearman's rank correlation (controlled for age and gender) revealed a moderate correlation between the B-CAA stages and (1) the progression of AD pathogenesis (control, p-preAD, AD) or (2) the degree of dementia, provided by the CDR score (P < 0.001, Table 2 ). Correlation of the B-CAA stages with the CDR score was restricted to cases without VD, CBD, LBD, and/or AGD to avoid bias caused by these co-morbidities. Furthermore, the anatomical expansion of amyloid plaques (Ab-MTL phases) as well as the B-Ab plaque stages, Braak-NFT stages, CERAD scores, and NIA-AA AD degrees showed a weak to moderate correlation with the B-CAA stages (P ≤ 0.001, Table 2 ). Interestingly, the B-CAA stages also correlated with the APOE e4 allele frequency similar to the CAA severity, the B-Ab plaque stages, and the Ab-MTL phases (P ≤ 0.003, Table 2 ). Linear regression (controlled for age and gender) furthermore revealed a negative association of arterial hypertension with the B-Ab plaque stages (P = 0.022, Table 6 ) but not with the B-CAA stages (P = 0.319, Table 6 ). Diabetes mellitus and alcohol abuse did not affect the B-CAA or B-Ab plaque stages (P ≥ 0.064, Table 6 ).
To clarify the impact of plaque-and CAA-related Ab maturation on the development of AD according to the NIA-AA AD criteria and the degree of dementia as described by the CDR score, we calculated two linear regression models (controlled for age and gender) including both B-CAA and B-Ab plaque stages. Plaque maturation (B-Ab plaque stages; P < 0.001, Table 6 ) but not CAA maturation (B-CAA stages; P = 0.248, Table 6 ) correlated with the progression of AD (NIA-AA AD degree). Accordingly, all symptomatic AD cases exhibited B-Ab plaque stage 3 but only 60% of symptomatic AD cases presented with B-CAA stage 3. Additional linear regression (restricted to cases without VD, CBD, LBD, and/or AGD) indicated that CAA maturation significantly contributed to the degree of cognitive decline (CDR score) (P = 0.005, Table 6 ). As expected from the finding that all cases with symptomatic AD exhibited B-Ab plaque stage 3, no additional impact of plaque-related Ab maturation on cognitive decline was detected (P = 0.173, Table 6 ).
Discussion
Biochemical stages of CAA-related Ab maturation (B-CAA stages)
The combined detection of different Ab variants revealed a hierarchical sequence of Ab deposition in CAA that could be differentiated into three distinct stages (Fig. 3A) : B-CAA stage 1 corresponded to the deposition of Ab not modified by pyroglutamination and/or phosphorylation; B-CAA stage 2 was characterized by the additional deposition of Ab N3pE ; and B-CAA stage 3, finally, included Ab pS8 . This sequential deposition of Ab in CAA corresponds to the previously observed hierarchical sequence for the deposition of modified Ab in plaques, 9 suggesting that vascular and parenchymal Ab deposition represent two aspects of a common biochemical process of Ab maturation. A common sequence of Ab deposition in CAA and plaques is indeed supported by the correlation of the B-CAA stages with the B-Ab plaque stages and with the anatomical expansion of amyloid plaques and CAAaffected blood vessels throughout the brain. Although studies with transgenic mouse models expressing the amyloid precursor protein in neurons 34 and on the drainage of parenchymal Ab 35 suggest a neuronal origin of Ab in CAA, it remains to be determined whether modified Ab species detected in the vasculature originate from the parenchyma or whether modification can occur within vessels. However, despite the common sequence of Ab deposition in CAA and plaques, the segregation of CAA and plaque pathology became particularly obvious through the case-by-case analysis of B-CAA and B-Ab plaque stages and the absent correlation of the B-CAA stages with amyloid plaque load.
Cross-sectional autopsy studies cannot prove the sequential deposition of Ab and its modified forms. However, the following arguments strongly support a sequential process: (1) none of the cases showed deposition of Ab pS8 in the absence of Ab N3pE , (2) the B-CAA stages correlate with the sequential expansion of plaques throughout the MTL 27 which correlates with increased amyloid PET-tracer retention, [36] [37] [38] and (3) the sequential occurrence of Ab and its modified forms in line with the B-Ab plaque stages within the human brain has been confirmed in a mouse model for AD. 39 Thus, there is at least indirect evidence that the B-CAA stages indeed represent a sequential process of Ab, Ab N3pE , and Ab pS8 deposition.
Case groups for plaque-and CAA-related Ab maturation (Ab pathology groups)
Despite the correlation of the B-CAA stages with the BAb plaque stages and the Ab-MTL phases, significant variations between the B-CAA and B-Ab plaque stages existed within individual cases. The specific composition of vascular and parenchymal Ab deposits indicated three distinct case groups for Ab pathology (Fig. 3B, Table 3 ): group 1 was defined by predominant Ab maturation in CAA (B-CAA stage > B-Ab plaque stage); group 2 included cases with equal Ab maturation in CAA and plaques (B-CAA stage = B-Ab plaque stage); and group 3 was characterized by predominant Ab maturation in plaques (B-CAA stage < B-Ab plaque stage), including cases without CAA. Interestingly, these case groups showed additional neuropathological associations. Cases with CAA-predominant pathology showed less advanced Ab-MTL phases for the anatomical expansion of plaque pathology, whereas cases with plaque-predominant pathology exhibited less widespread and severe CAA. Previous neuropathological studies revealed that CAA cases could differ in their relation between CAA severity and AD-related plaque pathology. 3, 7, [40] [41] [42] Thus, our finding of differences in the balance of Ab maturation between CAA and plaques might provide an explanation at the molecular level for the well-known variation in CAA in relation to plaque pathology. 3, 7, [40] [41] [42] The association of the CAA-predominant pathology group with arterial hypertension furthermore indicates that this condition could affect the leading site of Ab maturation and, thereby, might act as additional risk factor for Ab seeding and maturation. This is indeed supported by the development of CAA in a rat model for hypertension. 43 Thus, arterial hypertension should be taken into account for therapeutic intervention because it might modify the pathological picture of AD to the CAApredominant pattern.
The length of Ab could also play an important role in the balance between vascular and parenchymal Ab deposition. Ab 40 predominantly occurs within vascular Ab deposits whereas Ab 42 predominates in plaques. 44 Likewise, mouse models producing mainly Ab 40 develop a CAA-predominant Ab pathology and mice exhibiting augmented amounts of Ab 42 show negligible CAA pathology but abundant plaques. 45 The identification of B-CAA stages with the same Ab maturation sequence as plaques suggests that post-translational modifications could occur in both Ab 40 -and Ab 42 -predominant aggregates in blood vessels and parenchymal plaques. However, since vascular deposits in the human brain contain both Ab 40 and Ab 42 even in early stages of pathogenesis, 31, 44 it might require transgenic animal models to specifically address the question whether the ratio of Ab 40 and Ab 42 influences the site of Ab aggregate maturation.
Furthermore, the site of leading Ab maturation might attract further proteins to accumulate. This interpretation corresponds to the finding that seeds of Ab aggregates could induce further Ab deposition [46] [47] [48] and argues in favor of the view that the presence of local seeds determines the aggregation pattern. However, it will be important to investigate whether the apparent maturation of Ab in individual deposits results from addition of modified species to existing Ab aggregates or whether already aggregated Ab within deposits undergoes post-translational modification. Previously, we demonstrated Ab N3pE and Ab pS8 within non-detergent extracts of human and APP transgenic mouse brains, 9, 12, 17 indicative for the presence of these Ab variants in monomeric or soluble oligomeric form. Whether already aggregated and deposited Ab is amenable to pyroglutamination and/or phosphorylation is not known. Own preliminary studies suggest that Ab aggregates can be phosphorylated at serine 8 in vitro but further work would be required to proof that this could occur in vivo. It has also been shown that plaques and CAA in human and transgenic mouse brains contain N-terminally truncated Ab species 19, [49] [50] [51] [52] [53] that would also be detected by the antiAb 17-24 antibody used in this study. Since the cerebrovascular deposits were detected with antibodies raised against Ab [17] [18] [19] [20] [21] [22] [23] [24] and Ab 1-17, it is quite likely that these deposits contain non-truncated Ab. Only some early plaque types, such as fleecy amyloid, appeared to contain N-terminal truncated Ab with a non-identified N-terminus as reported previously. 54, 55 The simultaneous presence of truncated forms of Ab other than Ab N3pE be excluded. Additional to the aggregation-promoting effect, phosphorylation, and pyroglutamination also affect the proteolytic degradation of Ab monomers and the stability of Ab aggregates. 13, [56] [57] [58] Thus, pyroglutamination could potentially favor further phosphorylation and, thereby, increase the stability of Ab aggregates, and exaggerate Ab aggregation.
Contribution of CAA-related Ab maturation to cognitive decline
The B-CAA stages significantly correlated with the CDR score representing cognitive decline. However, only cases with equal maturation of Ab in CAA and plaques showed an association with cognitive decline, suggesting that Ab maturation in CAA represents only one of numerous factors that contribute to dementia. The mere presence of end-stage CAA maturation (that was observed both in CAA-predominant and equal maturation cases) seems to be insufficient to determine the development of dementia on its own. Rather end-stage plaque maturation has to be present. Accordingly, all symptomatic AD cases presented with end-stage plaque maturation. In contrast, only 60% of symptomatic AD cases exhibited full CAA maturation, supporting the importance of plaque maturation for the development of dementia. However, a multiple linear regression model revealed only the selective impact of CAA maturation on the CDR score, indicating that the impact of plaques on the development of dementia might only partially be ascribed to Ab maturation but that instead the high level of other AD neuropathologic changes that correlate with end-stage plaque maturation, such as NFT pathology, 59 might contribute to the course of dementia in AD.
Molecular characterization of amyloid pathology, based on the composition of CAA and plaques, might not only help to identify pathological subgroups of b-amyloidosis but also to understand the effect of therapeutic interventions. Ab immunization, for example, could reduce the amyloid load within plaques but simultaneously exacerbate CAA pathology and CAA-related hemorrhages. 60, 61 The association of CAA-predominant Ab maturation with arterial hypertension argues for a higher risk for therapyrelated bleedings in these patients as both CAA and arterial hypertension represent risk factors for intracerebral hemorrhages. 62, 63 
